Skip to content Skip to footer
Subscribe Now
Viewpoints_Txema Sanz
VIEWPOINTS

PharmaShots Interview: Astellas’ Txema Sanz Shares Insights on the Evrenzo (roxadustat) for Symptomatic Anemia Associated with Chronic Kidney Disease

In an interview with PharmaShots, Txema Sanz, Senior Vice President and Head of the Global Medical Specialties at Astellas shared his views on the EC's approval of Evrenzo (roxadustat) for the Treatment of symptomatic anemia associated with Chronic Kidney Disease Shots: The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with…
October 27, 2021

Read more

Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 2021

Read more

Viewpoints_Rich Birhanzel
VIEWPOINTS

PharmaShots Interview: Accenture’s Rich Birhanzel Shares Insight on the Investment in ixlayer

In an interview with PharmaShots, Rich Birhanzel, Senior Managing Director & Global Health Lead at Accenture shared his views on the investment in ixlayer to provide health solutions for diagnostic testing Shots: The company has made a strategic investment in ixlayer through Accenture Ventures to expand access to virtual diagnostic health testing. The company's telehealth platform allows players across the healthcare ecosystem…
October 22, 2021

Read more

Viewpoints_Anish Suri
VIEWPOINTS

PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting

In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 2021

Read more

Viewpoints_Brandon Smith
VIEWPOINTS

PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk

In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…
October 15, 2021

Read more

Viewpoints_Suela Sulo
VIEWPOINTS

PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care

In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how this study will shift the way to approach nutrition across the continuum of care. Shots: A study published in the Journal of Primary Care and Community Health has shown that a new…
October 13, 2021

Read more

Viewpoints_Dr. Pierre Pellier
VIEWPOINTS

PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD

In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBD Shots: CTMA developed the web mobile platform, CT-Scout to boost patient recruitment in the clinical trials by facilitating a quick and simple study detection for eligible patients CT-Scout is currently available in…
October 11, 2021

Read more

Viewpoints_Dr. Barbara Klencke
VIEWPOINTS

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153

In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…
October 11, 2021

Read more

Load more